Vaccine for protection against streptococcus suis
A technology of Streptococcus suis and vaccines, which is applied in the direction of veterinary vaccines, vaccines, antibacterial drugs, etc., and can solve the problems of short-term, failure to meet registration standards, and low level of heterologous protection
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0028] The aim of the first study was to test the IgM protease antigen, in this case that of S. suis serotype 2, against conventional bacterin vaccines containing inactivated serotype 2 S. suis bacteria (see PorcilisStrepsuis ) compared to whether it can provide protection against serotype 2 Streptococcus suis challenge.
[0029] Research design
[0030]Thirty weaned pigs were used. Pigs were allocated into three groups of 10 pigs each (evenly distributed across different litter ranges). Group 1 was treated with 230 μg per dose of recombinant rIdeSsuis IgM protease antigen (Seele et al: Vaccine33 as determined by Bradford protein assay using BSA as standard) in oil-in-water adjuvant at 5 and 7 weeks of age. :2207-2212; May 5, 2015, Section 2.2.) Two intramuscular vaccinations. Group 2 was vaccinated intramuscularly twice at 5 and 7 weeks of age with whole-cell bacterin of serotype 2 (see Porcilis Strepsuis) in oil-in-water adjuvant (positive control). Group 3 was not vacci...
Embodiment 2
[0038] The aim of the second study was to test whether the IgM protease antigen could confer protection against challenge with serotype 14 S. suis.
[0039] Research design
[0040] The design of the study was largely the same as that of the first study. Groups of 10 pigs were used and vaccinated twice at 5 and 7 weeks of age with IgM protease antigen (group 1 ) or as unvaccinated control animals (group 2). At 9 weeks of age, pigs were challenged with a highly pathogenic culture of S. suis serotype 14.
[0041] result
[0042] Also in this study, the vaccine did not induce any unacceptable local or systemic reactions. On the day of initial vaccination (5 weeks of age), most pigs had (maternal) antibody titers of approximately 4 log 2 . After vaccination, the vaccine group showed a good antibody response after booster immunization, with an average antibody titer of 9.3log2. Antibody titers in control animals remained low, with an average antibody titer of 4.1 log2. Post-c...
Embodiment 3
[0048] Since protection against S. suis in pigs is preferably obtained during the risk period (typically 4-7 weeks of age), a vaccine containing IgM protease was evaluated as a single dose at 3 weeks of age in maternally derived anti-S. suis positive pigs. Whether the vaccine is effective.
[0049] Research design
[0050] The study design was similar to that of the previous two studies, with the main difference being that 3-week-old anti-Ssuis MDA-positive piglets were vaccinated instead of 5-week-old animals (only 1 in 10 animals appeared to have less than MDA level of detection limit). Group 1 was inoculated once intramuscularly with IgM protease antigen in oil-in-water adjuvant. Group 2 served as the negative challenge control group. At 4 weeks of age, piglets were weaned. At 6 weeks of age, piglets were transported to the challenge chamber and challenged immediately. There was no acclimatization period between shipping and challenge to simulate natural stress. Pigle...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More